Hormonal
Pharmacological therapy with statins, fibrates, niacin, or thiazolidinediones (TZDs) can improve the atherogenic dyslipidemic phenotype in type 2 diabetes, leading to reduced coronary artery disease progression and cardiovascular events.
While diet and exercise are crucial, most people with type 2 diabetes and abnormal lipids will likely need medication to protect their heart. Drugs like statins, fibrates, or TZDs can significantly lower your risk of heart attacks and stroke by correcting specific blood fat abnormalities that lifestyle changes alone might not fully fix. Discuss these options with your doctor.
Clinical trials have shown significant improvement in coronary artery disease after diabetic dyslipidemia treatment. There are several classes of medications that can be used to treat lipid and lipoprotein abnormalities associated with insulin resistance and type 2 diabetes, including statins, fibrates, niacin, and thiazolidinediones.
Why this rating
Supported by multiple clinical trials (VA-HIT, SCRIP, etc.) and post-hoc analyses showing reduced events.
Source
Lipids and Lipoproteins in Patients With Type 2 Diabetes
Ronald M. Krauss · Diabetes Care · 2004
DOI 10.2337/diacare.27.6.1496
More from this paper
- In patients with type 2 diabetes, the characteristic dyslipidemia (low HDL, small dense LDL, elevated triglycerides) is strongly associated with increased cardiovascular disease risk, driven by insulin resistance and altered VLDL metabolism.Strong
- High-dose niacin (1,500 mg/day) improves the atherogenic lipoprotein profile in type 2 diabetes but may worsen glycemic control, whereas lower doses (1,000 mg/day) have minimal impact on glycemia.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →